McDermott is pleased to bring our Life Sciences Boot Camp for In-House Counsel back to the Bay Area!
Amid turbulent economic forces, life sciences companies continue to grapple with increasingly complex legal and business...more
3/21/2023
/ Acquisitions ,
Compliance ,
Continuing Legal Education ,
Corporate Counsel ,
Enforcement ,
Events ,
Food and Drug Administration (FDA) ,
Intellectual Property Litigation ,
Intellectual Property Protection ,
Life Sciences ,
Medical Devices ,
Mergers ,
NAD ,
Pharmaceutical Industry ,
Prescription Drugs
The US Court of Appeals for the Federal Circuit affirmed a lower court ruling that a claim must at a minimum include the recited enantiomer. Sumitomo Dainippon Pharma Co., Ltd. v. Emcure Pharmaceuticals Ltd., et al., Case No....more
Settlement agreement between a co-defendant and plaintiff in a Hatch-Waxman patent litigation matter is discoverable, ruled Judge Bryson in Allergan, Inc. v. Teva Pharmaceuticals, Inc. et al., Case No. 15-1455 (E.D. Tex.,...more
On-Sale Bar Is No Bar for Selling Manufacturing Services to the Inventor -
Addressing what constitutes an invalidating “sale” under § 102(b), the US Court of Appeals for the Federal Circuit sitting en banc affirmed the...more
11/4/2016
/ Abbreviated New Drug Application (ANDA) ,
Antitrust Violations ,
Appeals ,
Direct Infringement ,
Food and Drug Administration (FDA) ,
HIV ,
Indirect Infringement ,
Inventors ,
Manufacturers ,
Motion to Dismiss ,
On-Sale Bar ,
Patent Infringement ,
Patent Litigation ,
Patents ,
Pharmaceutical Industry ,
Product Hopping ,
Reverse Payments ,
Sherman Act
180-Day Notice Period for Biosimilar Approval Is Always Mandatory and Enforceable by Injunction -
Amgen Inc., v. Apotex Inc., (Fed. Cir. July 5, 2016) -
A year after analyzing the patent dance and notice...more
7/19/2016
/ Abbreviated New Drug Application (ANDA) ,
Actavis Inc. ,
Amgen ,
Assignments ,
Attorney-Client Privilege ,
Biosimilars ,
BPCIA ,
Federal Rule 12(b)(6) ,
Food and Drug Administration (FDA) ,
Hospira ,
Litigation Privilege ,
Merck ,
Method Claims ,
Motion to Dismiss ,
Obviousness ,
Patent Dance ,
Patent Infringement ,
Patents ,
Personal Jurisdiction ,
Pharmaceutical Industry ,
Product Exclusivity ,
Reverse Payment Settlement Agreements ,
Sandoz v Amgen ,
Summary Judgment ,
Unclean Hands ,
Work-Product Doctrine